Premium
Anti‐idiotypic monoclonal antibody AB3, reacting with the primary antigen (CEA), can localize in human colon‐carcinoma xenografts as efficiently as AB1
Author(s) -
De Moraes Jane Z.,
Gesztesi JeanLuc,
Westermann Patrick,
Le Doussal JeanMarc,
Lopes José D.,
Mach JeanPierre
Publication year - 1994
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910570424
Subject(s) - carcinoembryonic antigen , monoclonal antibody , in vivo , pathology , spleen , antigen , antibody , carcinoma , monoclonal , kidney , microbiology and biotechnology , medicine , cancer research , chemistry , biology , cancer , immunology
BALB/c mice were immunized with anti‐idiotypic monoclonal (MAb) antibody (anti‐Id or Ab2) directed against an ABI Mab anti‐carcinoembryonic (CEA) in order to obtain AB3 MAbs (anti‐anti‐Id). AB3 MAbs were shown to recognise the primary antigen (CEA) and one of them was tested extensively in vitro and in vivo. This AB3 MAb was shown to bind specifically to CEA on frozen sections of a human colon carcinoma by immunoper‐oxidase. Scatchard plot analyses showed that the affinity of this AB3 was of the same order of magnitude as the ABI. In vivo experiments, in nude mice bearing CEA‐producing human colon‐carcinoma xenografts showed that up to 30% of the intravenously injected dose of 125 I‐labelled AB3 were localized per gram of tumour tissue. Furthermore, calculation of the ratios of AB3 concentration in the tumour over those in normal organs such as lung, liver, kidney, spleen and bone gave relatively high values similar to results obtained with ABI. All together our results show that AB3 can localize as efficiently and specifically in the tumour as ABI, despite the fact that the mice from which it was derived were immunized with a mouse MAb (AB2) and had never been exposed to CEA. © 1994 Wiley‐Liss, Inc.